Table 1.
Baseline clinical characteristics of the study patients
| COPD | |
|---|---|
| Number | 274 |
| Gender, female, n (%) | 17 (6.2) |
| Age, years | 72.2 ± 7.9 |
| Smoking Index, pack-years | 55.2 ± 29.7 |
| Current smokers, n (%) | 26 (9.6) |
| BMI, kg/m2 | 22.9 ± 3.1 |
| FEV1/FVC, % | 52.4 ± 12.3 |
| % FEV1, % | 63.3 ± 21.1 |
| GOLD grade 1/2/3/4, n (%) | 63/134/61/16 (23.0/48.9/22.3/5.8) |
| Baseline CAT score | 12.2 ± 8.0 |
| LAMA, n (%) | 170 (62.0) |
| LABA, n (%) | 136 (49.6) |
| ICS, n (%) | 93 (33.9) |
| Dose of ICSa, μg/day, median | 500 |
| WBC, n | 6208 ± 1566 |
| Neutrophil, % | 60.3 ± 8.9 |
| Neutrophil, n | 3797 ± 1320 |
| Lymphocyte, % | 29.2 ± 8.2 |
| Lymphocyte, n | 1770 ± 553 |
| NLR | 2.1(1.6–2.7) |
| Eosinophil, % | 3.4 ± 2.6 |
| Eosinophil, n | 204 ± 150 |
Data are shown as mean ± SD and median (interquartile range)
COPD chronic obstructive pulmonary disease, BMI body mass index, FEV1 forced expiratory volume in one second, FVC forced vital capacity, % FEV1 ratio of predicted FEV1, GOLD Global Initiative for Chronic Obstructive Lung Disease, CAT COPD assessment test, LAMA long-acting muscarinic antagonist, LABA long-acting β2 agonist, ICS inhaled corticosteroids, WBC white blood cell, NLR Neutrophil-to-Lymphocyte ratio
aDose of inhaled corticosteroid is shown as fluticasone propionate equivalent